Striking HIV-1 Entry by Targeting HIV-1 Gp41. But, Where Should We Target?

PLoS ONE - United States
doi 10.1371/journal.pone.0146743
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Design of Potent Inhibitors of HIV-1 Entry From the Gp41 N-Peptide Region

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2001English

Amphipathic Properties of HIV-1 Gp41 Fusion Inhibitors

Current Topics in Medicinal Chemistry
MedicineDrug Discovery
2011English

Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?

Immunity
Infectious DiseasesAllergyImmunology
2010English

Enhancement of Endocytic Uptake of HIV-1 Virions Into CD4-negative Epithelial Cells by HIV-1 Gp41 via Its Interaction With POB1

Cellular and Molecular Immunology
Infectious DiseasesMedicineAllergyImmunology
2015English

CXCR7/ACKR3-targeting Ligands Interfere With X7 HIV-1 and HIV-2 Entry and Replication in Human Host Cells

Heliyon
Multidisciplinary
2018English

Template-Constrained Cyclic Sulfopeptide HIV-1 Entry Inhibitors

Organic and Biomolecular Chemistry
Organic ChemistryTheoretical ChemistryBiochemistryPhysical
2013English

Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human Α-Defensin

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2012English

Antibodies to the Primary Immunodominant Domain of Human Immunodeficiency Virus Type 1 (HIV-1) Glycoprotein Gp41 Enhance HIV-1 Infection in Vitro.

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
1990English

Synthesis of Betulinic Acid Derivatives as Entry Inhibitors Against HIV-1 and Bevirimat-Resistant HIV-1 Variants

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy